Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25254799 | 1.00 | MGLL (0.46) | MGLLKCNH2CACNA1CSCN5ACYP11B1 | |
| SCHEMBL25297074 | 1.00 | MGLL (0.46) | MGLLKCNH2CACNA1CSCN5ACYP11B1 | |
| SCHEMBL25251468 | 0.88 | MGLL (0.45) | MGLLCYP11B1CYP11B2IDO1NAAA | |
| SCHEMBL25297883 | 0.86 | MGLL (0.37) | MGLL | |
| SCHEMBL25261715 | 0.86 | MGLL (0.46) | MGLLKCNH2CACNA1CSCN5ACYP11B1 | |
| SCHEMBL25254968 | 0.86 | MGLL (0.46) | MGLLKCNH2CACNA1CSCN5ACYP11B1 | |
| SCHEMBL25253572 | 0.85 | MGLL (0.41) | MGLLCYP11B1CYP11B2IDO1NAAA | |
| SCHEMBL25250350 | 0.85 | MGLL (0.43) | MGLLCYP11B1CYP11B2IDO1NAAA | |
| SCHEMBL28986570 | 0.84 | KCNH2 (0.40) | MGLLKCNH2CACNA1CSCN5ACYP11B1 | |
| SCHEMBL25302965 | 0.83 | CYP11B1 (0.40) | MGLLCYP11B1CYP11B2IDO1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | MGLL 996/4885KCNH2 792/4885CACNA1C 1547/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | MGLL 996/4885KCNH2 792/4885CACNA1C 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.